Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

Vertex Pharmaceuticals (VRTX) closed at $468.09 in the latest trading session, marking a +0.94% move from the prior day.

Vertex Pharmaceuticals Incorporated looks set for two new drug approvals in early 2025. Click here to read an analysis of ...

Currently trading with a volume of 891,270, the VRTX's price is down by -3.75%, now at $451.64. RSI readings suggest the stock is currently is currently neutral between overbought and oversold.

The stock's fall snapped a two-day winning streak.

This was the stock's second consecutive day of gains.

Pain has really been out of favor in the industry up until very recently,” said John Mulcahy, SiteOne Therapeutics’ CEO. The ...

Stifel raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $494 from $490 and keeps a Hold rating on the shares. With shares up ...

Vertex Pharmaceuticals (VRTX) ended the recent trading session at $468.09, demonstrating a +0.94% swing from the preceding day's closing price. This change outpaced the S&P 500's 0.38% gain on the ...

Fintel reports that on December 9, 2024, Jefferies upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from ...